[Protective effect of continual administration of glycine following exposure to LD 100-15 x-radiation. I].
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D005260:Female; D005998:Glycine / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D008099:Liver / Q000201:enzymology / Q000528:radiation effects; D051379:Mice; D011755:Pyrophosphatases / Q000378:metabolism; D011833:Radiation Injuries, Experimental / Q000188:drug therapy* / Q000401:mortality; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D013997:Time Factors
D011837:Radiation-Protective Agents; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000251:Adenosine Triphosphatases; D011755:Pyrophosphatases; D005998:Glycine
L'effet protecteur de la glycine en administration chronique après l'irradiation aux rayons X DL100-15.